Search clinical trials for: BI 655130

Total 1219 results

Boehringer Ingelheim

Terminated

A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

Macular Degeneration

United Kingdom, United States
University of Chicago
CHEST Foundation

Completed

Virtual Teach-to-Goal Education vs. Brief Education for Children (V-TTG vs BI)

Asthma | Shortness of Breath | Bronchospasm

United States
Medtronic Cardiac Rhythm and Heart Failure

Completed

Application of Right Atrial Left Ventricular Fusion Pacing in Patients With CRT Indications

Heart Failure

China
Brigham and Women's Hospital
Massachusetts General Hospital

Withdrawn

Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)

Chronic Obstructive Airway Disease

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers

Healthy

Germany
Daping Hospital and the Research Institute of Surgery...

Unknown

A Study of Bi-Level Positive Airway Pressure (BIPAP) Versus Non Invasive Positive Pressure Ventilation (NIPPV) for Neonatal Respiratory Failure (BIPAP)

Neonatal Respiratory Failure

China
Boehringer Ingelheim

Completed

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

Healthy
Boehringer Ingelheim

Recruiting

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Solid Tumors

Spain, Canada, United States, Sweden
Boehringer Ingelheim

Terminated

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Purpura, Thrombocytopenic, Idiopathic

United States
Boehringer Ingelheim

Terminated

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

Neoplasms

United States, Spain, Japan, Netherlands
AbbVie

Completed

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems

Hepatic Insufficiency | Healthy

United States
University of Chicago

Completed

Teaching Use of Respiratory Inhalers (TURI) (TURI)

Asthma | COPD

United States
Albert Einstein College of Medicine

Terminated

Bi-Level Positive Airway Ventilation for Acute Chest Syndrome

Sickle Cell Anemia | Acute Chest Syndrome

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

Hemorrhage

Belgium
Queen's University
Canadian Institutes of Health Research (CIHR)

Completed

Prevention and Reduction of Obesity Through Active Living (PROACTIVE)

Obesity

Canada
Biosense Webster, Inc.

Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF (SMARTPULSE PAF)

Drug Refractory Paroxysmal Atrial Fibrillation

United States
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Wet Macular Degeneration

United Kingdom, United States, Germany
AbbVie

Completed

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)

Psoriasis

Russian Federation
University of Pittsburgh
Merck Sharp & Dohme LLC; RTI International; Rite Aid Corp.; Pharmacy Quality Alliance

Completed

Effect of Community Pharmacist Intervention on Adherence to Long-Term Medications (ECO-PHIL)

Medication Adherence

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects

Healthy
Bayside Health
National Health and Medical Research Council, Australia; Monash University; Cystic...

Completed

Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation

Cystic Fibrosis

Australia
Boehringer Ingelheim

Completed

Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, China, France, Germany, India, Korea, Republic of, Mexico, Slovakia, Slovenia, Taiwan, Turkey
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
Boehringer Ingelheim

Recruiting

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Lung Neoplasms | Pancreatic Neoplasms | Bladder Cancer | Solid Tumors | Biliary Tract Cancer

United States, Korea, Republic of, Spain, Australia, Japan, Germany, Taiwan, Singapore, Thailand, France, Belgium, Austria, Switzerland, United Kingdom
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

Liver Cirrhosis | Hypertension, Portal

Spain, Germany, Canada, China, Austria, United States, Japan, France, Korea, Republic of, Romania
Boehringer Ingelheim

Completed

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

Depressive Disorder, Major

United States
Boehringer Ingelheim

Completed

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Prostatic Neoplasms, Castration-Resistant

Korea, Republic of, United States, Spain, Taiwan, United Kingdom, Singapore, Hong Kong, Netherlands
Boehringer Ingelheim

Terminated

A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression

Depressive Disorder, Major

United States
Boehringer Ingelheim

Completed

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225

Healthy

Germany
Universidade Federal do Rio Grande do Norte

Completed

Non Invasive Ventilation on Peripheral Muscle Function and Aerobic Performance (NIV)

Chronic Obstructive Pulmonary Disease

Brazil
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 456906 in Patients With Obesity

Obesity

Germany
Kyungpook National University Chilgok Hospital
Kyungpook National University Hospital

Completed

Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Stomach Neoplasms

Korea, Republic of
Boehringer Ingelheim

Completed

Olmutinib (BI 1482694) ADME Study

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety of Single Rising Doses and Relative Bioavailability of BI 691751

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses of BI 44370 BS Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Withdrawn

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667

Healthy
Boehringer Ingelheim

Completed

Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.

Healthy

Germany
Boehringer Ingelheim

Completed

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Japan
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD

Pulmonary Disease, Chronic Obstructive

Japan
University of Colorado, Denver
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial

Asthma in Children

United States
University of Manitoba
Canadian IBD Research Consortium (CIRC)

Not yet recruiting

Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease.

Crohn Disease | Ulcerative Colitis
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine

Depressive Disorder, Major

United States
Erasmus Medical Center

Enrolling by invitation

Validation of SMS Protocol for HCC Screening in High-risk Patients

Hepatocellular Carcinoma

Netherlands
Boehringer Ingelheim

Completed

An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis

Lupus Nephritis

United Kingdom, Thailand, Germany, Japan, United States, Australia, Korea, Republic of, Hong Kong, Poland, Greece, Mexico, Czechia, Canada, Malaysia, Philippines, Portugal
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2

Healthy

Japan
Biointegrator LLC

Terminated

Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab

Metastatic Breast Cancer

Russian Federation
Boehringer Ingelheim

Completed

Safety Tolerability and Pharmacokinetic of BI 411034

Healthy

Germany
Boehringer Ingelheim

Completed

Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

Diabetes Mellitus, Type 2

Germany

3

Subscribe